US FDA approves Mesoblast's cell therapy for graft-versus-host disease
The U.S. Food and Drug Administration on Wednesday approved Mesoblast's cell therapy for treating a type of complication that ...
clinicaladvisor.com6h
Mesenchymal Stromal Cell Therapy Ryoncil Gets FDA Approval
The Food and Drug Administration (FDA) has approved Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft vs host disease (SR-aGvHD) in pediatric patients 2 months of age ...
Mesoblast Finally Gets Its Approval In GVHD: Where Now?
Investment risks and competition challenge Mesoblast Limited's recent approval for Remestemcel-L in treating ...
Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges
Mesoblast's Ryoncil is now FDA-approved for pediatric SR-aGvHD, marking a milestone in mesenchymal stromal cell therapies in ...
emjreviews.com3d
PET Imaging Technique Identifies Early Graft-Versus-Host Disease
New imaging technique able to identify early signs of graft-versus-host-disease in transplant patients. Read on!
Rolling Out1d
What you need to know about bone marrow transplants
This phase can last months, requiring various protective measures to prevent complications. Graft-versus-host disease remains ...
Medpage Today on MSN7d
FDA Approves Mesenchymal Stromal Cell Therapy for Refractory Acute GVHD in Kids
Reaching the end of a long road to approval, the first mesenchymal stromal cell (MSC) therapy for steroid-refractory acute ...
Zacks.com on MSN7d
MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease
The FDA approves Mesoblast's Ryoncil (remestemcel-L) for treating pediatric patients with steroid-refractory acute graft ...
Benzinga.com7d
What's Going On With Mesoblast Shares Thursday?
Mesoblast announces that the FDA approved Ryoncil. Ryoncil is the only approved therapy for steroid-refractory acute graft ...
Neutrolis Licenses University of Illinois Chicago Patent to Advance Topical Dry Eye Disease Therapy Targeting NETs
“It is clear that NETs contribute to DED and this licensing agreement represents an important step in bringing our innovative treatments to patients who live with the daily challenges of DED,” said ...
Business Insider7d
FDA Approves Mesoblast's Cell Therapy To Treat Steroid-refractory Acute Graft-versus-host Disease
These MSCs are isolated from the bone marrow of healthy adult human donors. Steroid-refractory acute graft-versus-host disease is a serious and life-threatening condition that can occur as a ...